SEC Form 4 · accession 0001837798-26-000013
Aurinia Pharmaceuticals Inc. · AUPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen P. Robertson
Officer — Chief Legal Officer
Period of report
Aug 21, 2026
Accepted (ET)
Aug 25, 2026 · 9:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001600620
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Aug 21, 2026 | S | 20,975 | $16.97 | D | 600,787 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Performance Stock Units (PSUs) related to the February 28, 2025 performance award.
- F2The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.96 to $17.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Includes 360 common shares that were acquired on May 29, 2026 by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan.